Wang Dingding, Wang Xiaoyi, Wu Kunfang, Wang Juanjuan, Xu Guihua, Chen Zilin
Ophthalmological Center of Huizhou Municipal Central Hospital, Huizhou, Guangdong 516000, P.R. China.
Exp Ther Med. 2019 Mar;17(3):1563-1568. doi: 10.3892/etm.2018.7125. Epub 2018 Dec 21.
The aim of this study was to evaluate the clinical efficacy of an intravitreal injection of ranibizumab combined with argon ion laser photocoagulation therapy in the treatment of different degrees of central retinal vein occlusion (CRVO). A total of 112 CRVO patients including 25 cases of trunk occlusion, 50 cases of branch occlusion and 37 cases of hemiretinal vein-occlusion were enrolled in this study. Patients were treated with an intravitreal injection of 0.5 mg ranibizumab, followed by argon ion laser photocoagulation therapy after 7 days. Patients were followed up for 6 months and the best corrected visual acuity (BCVA), central retinal thickness (CRT), macular edema, and surgical complications were compared. Compared with the control treated with 0.5 mg ranibizumab, the BCVA and macular edema improved while CRT was significantly reduced in all groups treated with 0.5 mg ranibizumab combined with the argon ion laser. Furthermore, no obvious complications were observed in these groups and the effects of ranibizumab combined with argon ion laser photocoagulation on branch occlusion group were the best. Intravitreal injection of ranibizumab combined with argon ion laser photocoagulation therapy has better safety and effectiveness in the treatment of different degrees of CRVO. The trial registration number is 2015-318 and date of registration is 12/10/2015.
本研究旨在评估玻璃体内注射雷珠单抗联合氩离子激光光凝疗法治疗不同程度视网膜中央静脉阻塞（CRVO）的临床疗效。本研究共纳入112例CRVO患者，其中包括25例主干阻塞、50例分支阻塞和37例半侧视网膜静脉阻塞患者。患者接受玻璃体内注射0.5mg雷珠单抗治疗，7天后进行氩离子激光光凝治疗。对患者进行6个月的随访，比较最佳矫正视力（BCVA）、视网膜中央厚度（CRT）、黄斑水肿及手术并发症情况。与单纯接受0.5mg雷珠单抗治疗的对照组相比，所有接受0.5mg雷珠单抗联合氩离子激光治疗的组中，BCVA和黄斑水肿均有改善，CRT显著降低。此外，这些组中未观察到明显并发症，且雷珠单抗联合氩离子激光光凝对分支阻塞组的效果最佳。玻璃体内注射雷珠单抗联合氩离子激光光凝疗法治疗不同程度的CRVO具有更好的安全性和有效性。试验注册号为2015 - 318，注册日期为2015年10月12日。
